Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M68.0Revenue (TTM) $M24.8Net Margin (%)-71.6Altman Z-Score-1.6
Enterprise Value $M193EPS (TTM) $-3.3Operating Margin %-108.8Piotroski F-Score1
P/E(ttm)--Beneish M-Score11.8Pre-tax Margin (%)-66.0Higher ROA y-yY
Price/Book0.910-y EBITDA Growth Rate %-27.7Quick Ratio3.8Cash flow > EarningsN
Price/Sales3.25-y EBITDA Growth Rate %-18.4Current Ratio4.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-5.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-57.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M14.6ROIC % (ttm)-68.8Gross Margin Increase y-yN

Gurus Latest Trades with OREX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

OREX is held by these investors:



OREX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Moglia Stephen A.VP, Chief Accounting Officer 2016-12-19Sell800$1.96137.76view
Booth Mark DChief Commercial Officer 2015-02-26Sell5,000$56.8-91.8view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-12-02Sell2,264$60-92.23view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-11-25Sell3,139$58.3-92.01view
BOCK LOUIS CDirector 2014-11-18Buy133$55.8-91.65view
BOCK LOUIS CDirector 2014-11-12Buy2,705$55.7-91.63view
Turner Heather DVP, Gen. Counsel & Secretary 2014-09-22Sell30,000$44.7-89.57view
NARACHI MICHAELPresident and CEO 2014-09-15Buy5,000$47.8-90.25view
Hagan Joseph PSr. VP, Corporate Development 2014-09-15Buy500$46.9-90.06view
Hagan Joseph PChief Business Officer 2013-07-31Sell1,200$78-94.03view

Quarterly/Annual Reports about OREX:

News about OREX:

Articles On GuruFocus.com
Seth Klarman’s Largest New Buys and Adds Feb 15 2016 
Value Investing in BioPharma Nov 18 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
Oxford Industries (OXM) Solid Growth Metrics, Orexigen Therapeutics (OREX) European Anti-Obesity App Mar 27 2015 
Orexigen Therapeutics' Bright Future Mar 03 2015 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 

More From Other Websites
Biotech's Rise Shows No Sign of Slowing Down in 2017: Today's Reports on IntelliPharmaCeutics and... Feb 27 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Feb 24 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results... Feb 17 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 09 2017
Orexigen Therapeutics to Speak at Upcoming Investor Conferences Feb 07 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 06 2017
Orexigen Therapeutics Announces Spanish Launch of Mysimba® (naltrexone HCl / bupropion HCl... Jan 25 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 12 2017
Orexigen Therapeutics (OREX) Shares March Higher, Can It Continue? Jan 10 2017
Celgene Issues Preliminary 2016 Results, Lifts 2017 View Jan 10 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 09 2017
Orexigen Therapeutics Announces Publication of Contrave® (naltrexone HCl and bupropion HCl... Jan 06 2017
Orexigen Therapeutics Announces Publication of Contrave® (naltrexone HCl and bupropion HCl... Jan 06 2017
Orexigen Therapeutics Highlights Key Business Priorities for 2017 Jan 05 2017
Orexigen Therapeutics Highlights Key Business Priorities for 2017 Jan 05 2017
Wednesday’s Top 5 Biopharma Movers Jan 04 2017
Orexigen Therapeutics Launches "Brains Behind Weight Loss," a Dynamic Patient Focused Campaign to... Jan 03 2017
Orexigen Therapeutics Launches "Brains Behind Weight Loss," a Dynamic Patient Focused Campaign to... Jan 03 2017
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events Dec 30 2016
15 Stocks With The Highest Forecast Sales Growth Dec 23 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)